CLVT

Clarivate Plc's stock (CLVT) has experienced a significant decline over the past year, with a 54.61% decrease over the last 12 months and a -43.43% year-to-date return as of September 15, 2026, reaching an all-time low of $1.66 on February 22, 2026. Key events impacting the stock price in the past six months include the reporting of Q4 and FY 2025 results on February 24, 2026, which showed a net loss and declining revenues, alongside the announcement of the potential sale of its Life Sciences & Healthcare business. On April 29, 2026, Q1 2026 earnings also reported a net loss and decreased revenue. An investor call on July 6, 2026, regarding the divestiture of its Life Sciences & Healthcare segment to Altaris LLC for $600 million, which included a significant non-cash goodwill impairment charge, led to an 11.35% stock drop on July 8, 2026, reflecting market anxiety over restructuring and debt. Q2 2026 results reported on July 29, 2026, showed total revenues of $587.3 million, down from the previous year due to inorganic divestitures. In August 2026, Clarivate expanded agentic AI capabilities across its Cortellis portfolio. On September 17, 2026, the company commenced an offer to purchase certain outstanding debt securities for cash and revealed its Citation Laureates 2026. Finally, on September 22, 2026, Clarivate announced its Q3 2026 results would be reported on November 3, 2026, and appointed Michael Easton as Chief Financial Officer.